In the latest trading session, 0.75 million G1 Therapeutics Inc (NASDAQ:GTHX) shares changed hands as the company’s beta touched 1.74. With the company’s most recent per share price at $1.79 changing hands around $0.22 or 14.01% at last look, the market valuation stands at $92.79M. GTHX’s current price is a discount, trading about -369.27% off its 52-week high of $8.40. The share price had its 52-week low at $1.08, which suggests the last value was 39.66% up since then. When we look at G1 Therapeutics Inc’s average trading volume, we note the 10-day average is 0.39 million shares, with the 3-month average coming to 515.08K.

Analysts gave the G1 Therapeutics Inc (GTHX) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 1.71. If we narrow down to specifics, the data shows that 1 out of 7 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended GTHX as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. G1 Therapeutics Inc’s EPS for the current quarter is expected to be -$0.3.

G1 Therapeutics Inc (NASDAQ:GTHX) trade information

Instantly GTHX is in green as seen in intraday trades today. With action 23.45%, the performance over the past five days has been green. The jump to weekly highs of 1.9000 on Friday, 11/17/23 added 14.01% to the stock’s daily price. The company’s shares are showing year-to-date downside of -67.03%, with the 5-day performance at 23.45% in the green. However, in the 30-day time frame, G1 Therapeutics Inc (NASDAQ:GTHX) is 21.77% up. Looking at the short shares, we see there were 2.44 million shares sold at short interest cover period of 3.8 days.

The consensus price target for the stock as assigned by Wall Street analysts is $8.40, meaning bulls need an upside of 78.69% from its recent market value. According to analyst projections, GTHX’s forecast low is $5.00 with $14.00 as the target high. To hit the forecast high, the stock’s price needs a -682.12% plunge from its current level, while the stock would need to soar -179.33% for it to hit the projected low.

G1 Therapeutics Inc (GTHX) estimates and forecasts

Data shows that the G1 Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -37.85% over the past 6 months, a 70.41% in annual growth rate that is considerably higher than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for G1 Therapeutics Inc will rise 58.90%, while the growth in revenue is estimated to hit 47.20% for the next quarter. Year-over-year growth is forecast to reach 57.50% up from the last financial year.

Consensus estimates given by 6 financial analysts project the company’s revenue in the current quarter to hit an average of $13.07 million. 4 analysts are of the opinion that G1 Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $15.68 million. The company’s revenue for the corresponding quarters a year ago was $10.25 million and $12.95 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 27.50%. The estimates for the next quarter sales put growth at 21.10%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -10.99%. The 2023 estimates are for G1 Therapeutics Inc earnings to increase by 70.67%.